Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects
- 7 October 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 1057-1065
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity, metabolic syndrome, and insulin resistance (IR). In IR associated with obesity or lipodystrophy (LD), caused by missing adipose tissue, hyperinsulinemia stimulates hepatic lipogenesis, causing steatotic liver disease (SLD). In contrast, insulin receptor pathogenic variants (INSR), despite hyperinsulinemia and IR, do not promote hepatic lipogenesis and steatosis. We aimed to understand SLD pathophysiology by comparing serum proteomic signatures of MASLD, LD, and INSR. Methods: Single-center study of fasting serum proteome using SomaScan assay in 30 LD, 29 INSR, and 16 people with MASLD. Key targets were assessed in the hepatic transcriptome of patients with MASLD (n = 19) and in HepG2 cells. Results: Of 6412 proteins, 567 differed between at least 2 groups. The proteome profiles clearly separated INSR from the other groups, whereas MASLD and LD displayed similarity, primarily in proteins involved in metabolism, liver injury, and fibrosis. Several proteins were uniquely elevated in INSR and LD compared to MASLD, particularly Factor IX and liver-expressed antimicrobial peptide 2. Serum levels of Factor IX and liver-expressed antimicrobial peptide 2 correlated with their hepatic expression, with in vitro expression unaffected by leptin, insulin, or glucose treatment. Conclusion: This first comparative proteomics study identified shared and unique pathways in IR disorders. MASLD and LD share features, suggesting similar drivers of liver disease progression. Key liver-derived proteins differ between MASLD, INSR, and LD because of unique disorder features. We demonstrate the utility of proteomics and rare disorder studies in interrogating pathogenesis of common disorders like MASLD.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- Office of Dietary Supplements
This publication has 32 references indexed in Scilit:
- Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver diseaseJournal of Hepatology, 2022
- Serum proteome profiling reveals differentially expressed proteins between subjects with metabolically healthy obesity and nonalcoholic fatty liver diseaseJournal of Proteomics, 2022
- ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLDJournal of Hepatology, 2021
- SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASHHepatology Communications, 2021
- Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesisRedox Biology, 2020
- Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response PhenotypesCell Reports, 2019
- Liver – master and servant of serum proteomeJournal of Hepatology, 2018
- Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effortHepatology, 2018
- Adipocytokines and hepatic fibrosisTrends in Endocrinology & Metabolism, 2015
- Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics2012